109099-51-6

Basic information

• Product Name: N-(4,6-dimethoxy-[1,3,5]triazin-2-ylamino)-benzenesulfonamide
• CAS NO: 109099-51-6
• Molecular Weight: 311.321
• Mol File: 109099-51-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(4,6-dimethoxy-[1,3,5]triazin-2-ylamino)-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4,6-dimethoxy-[1,3,5]triazin-2-ylamino)-benzenesulfonamide(109099-51-6)
• EPA Substance Registry System: N-(4,6-dimethoxy-[1,3,5]triazin-2-ylamino)-benzenesulfonamide(109099-51-6)

Safety Data

• Hazardous Substances Data: 109099-51-6(Hazardous Substances Data)

Upstream product

• 63-74-1 sulfanilamide 
• 67-56-1 methanol 
• 51757-37-0 4-(4',6'-dichloro-1',3',5'-triazin-2'-ylamino)-benzene-sulfonamide 
• 3140-73-6 2-chloro-4,6-dimethoxy-1 ,3,5-triazine 

Relevant articles and documents

Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties

A series of benzenesulfonamide derivatives incorporating triazine moieties in their molecules was obtained by reaction of cyanuric chloride with sulfanilamide, homosulfanilamide, or 4-aminoethylbenzenesulfonamide. The dichlorotriazinyl-benzenesulfonamides intermediates were subsequently derivatized by reaction with various nucleophiles, such as water, methylamine, or aliphatic alcohols (methanol and ethanol). The library of sulfonamides incorporating triazinyl moieties was tested for the inhibition of three physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isozymes, the cytosolic hCA I and II, and the transmembrane, tumor-associated hCA IX. The new compounds reported here inhibited hCA I with KIs in the range of 75-136 nM, hCA II with KIs in the range of 13-278 nM, and hCA IX with KIs in the range of 0.12-549 nM. The first hCA IX-selective inhibitors were thus detected, as the chlorotriazinyl-sulfanilamide and the bis-ethoxytriazinyl derivatives of sulfanilamide/homosulfanilamide showed selectivity ratios for CA IX over CA II inhibition in the range of 166-706. Furthermore, some of these compounds have subnanomolar affinity for hCA IX, with KIs in the range 0.12-0.34 nM. These derivatives are interesting candidates for the development of novel unconventional anticancer strategies targeting the hypoxic areas of tumors. Clear renal cell carcinoma, which is the most lethal urologic malignancy and is both characterized by very high CA IX expression and chemotherapy unresponsiveness, could be the leading candidate of such novel therapies.